Detail akcie Genfit online

Business Summary: Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Genfit SA revenues increased from EUR15.4M to EUR61.2M. Net income applicable to common stockholders totaled EUR30.3M vs. loss of EUR20.9M. Revenues reflect Revenue increase from EUR11.5M to EUR59M. Net Income reflects R&D Subcontractors decrease of 45% to EUR7.8M (expense), Foreign exchange losses decrease of 93% to EUR42K (expense), Other Operating Expense decrease of 14% to EUR2.8M (expense).